| INTRODUCTION
Closely associated with obesity, non-alcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease in children. 1 It encompasses a spectrum of disease, ranging from fatty liver to non-alcoholic steatohepatitis (NASH), with active inflammation and fibrosis. NASH is a more advanced state of NAFLD, during which some children will develop cirrhosis and end-stage liver disease. 2 NASH is associated with an increased risk of liver cancer. 3 Obesity, insulin resistance, and type 2 diabetes are established risk factors for NAFLD in children, 4 and the prevalence of type 2 diabetes in the pediatric population in the United States has increased significantly in recent years 5, 6 paralleling the corresponding rise in pediatric obesity.
A prior study has shown an estimated prevalence of type 2 diabetes of 6.5% in a cohort of 675 children with NAFLD, and children with type 2 diabetes had a 43% prevalence of NASH. 7 Dyslipidemia and elevated liver transaminases including alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are commonly associated with NAFLD and are also commonly seen in patients with type 2 diabetes. 8 The report by Newton et al. 7 describes those with type 2 diabetes as but is not diagnostic. 11 Histologic characteristics such as steatosis grade (0-3, a score of 0 indicating <5%, 1 indicating 5%-33%, 2 indicating 34%-66%, and a score of 3 indicating >66%), fibrosis stage (0-4, with a 0 indicating no fibrosis, 1 indicating perisinusoidal and/or portal fibrosis, 2 indicating perisinusoidal and periportal fibrosis, 3 indicating bridging fibrosis, and 4 indicating cirrhosis), lobular inflammation, and balloon degeneration (none, few, many) are evaluated.
In this study, all biopsies were evaluated by one senior pathologist with extensive experience in liver pathology and assessed using the NASH CRN scoring system. A diagnosis of NASH was made independent of the NAS, based on the pattern of injury and clinical assessment of the reading pathologist. Biopsies were categorized as having definite NASH, having borderline NASH, or no NASH. Labs including highest transaminase levels (AST, ALT) and lipid panel results within 6 months of the biopsy and hemoglobin A1c value nearest to the time of biopsy were used to correlate with NAS. Nine subjects (6 female, 3 male) had NAS < 3 (24%). As in none of the subjects without NASH or with borderline NASH had any advanced fibrosis observed (Figure 1 ). Three out of six subjects (50%)
with ballooning in many cells had stage 3 fibrosis, whereas only 2 out 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; HDL, high-density lipoprotein; NAS, NAFLD Activity Score; TG, triglycerides. Data are presented as mean (SD) for continuous variables and count (%) for categorical variables. a A1c conversions: 6.2% = 44 mmol/mol, 6.6% = 49 mmol/mol, 6.9% = 52 mmol/mol, 7.5% = 58 mmol/mol. ALT showed a weaker correlation (r = 0.3, with a trend P = 0.086).
HDL was lower (P = 0.022) in males (32 mg/dL) vs females (41 mg/ dL), and TG was higher (P = 0.038) in males (471 mg/dL) vs females (193 mg/dL). No other gender or ethnic differences between Hispanic and non-Hispanic subjects were noted. Subjects with NAS ≥ 4 had higher A1c levels (P = 0.037) and higher TG levels (P = 0.014) than those with NAS < 4 ( Table 2 ). We reached the same findings when comparing those with NASH only to those without NASH, or when we added the five subjects with borderline NASH to those without NASH.
In eight subjects with a second biopsy (range 1.7-5.6 years later), NAS was equal (37.5%) or improved (62.5%), and mean NAS decreased from 3.75 to 2.5 (NS). At their initial biopsy, five had NASH, and on repeat biopsy one converted to no NASH and one became borderline NASH. Two had no NASH, and one was borderline NASH at their first biopsy, and remained the same on the repeat biopsy. FIGURE 2 Correlations between NAFLD Activity Score (NAS) and metabolic parameters affected by outliers. There was an overall positive correlation with decreased liver enzyme levels and NAS, with a better correlation of AST (r = 0.66) compared with ALT (r = 0.37). However, with the exception of change in steatosis, no statistically significant correlations were noted between changes in A1c, TG, cholesterol, AST, ALT, or BMI Z-score and NAS in subjects with repeat biopsies. Complete data for this group were limited, and the lack of statistical significance likely reflects the small sample size.
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| DISCUSSION
We studied the relationship between liver histology and metabolic phenotype in obese pediatric patients with type 2 diabetes. We also assessed the correlation between the NAS and the presence or absence of NASH.
Liver histology and associations: Our study results showed that there was a high rate of NASH (60.5%) in our study cohort of 38 pediatric patients with type 2 diabetes. This is not a true prevalence, as we did not biopsy all patients with type 2 diabetes. It does not reflect just patients with very high transaminase levels, as we had many patients with transaminase elevations under twice normal. The rate of NASH we noted is consistent with findings from prior studies, which have shown increased odds of NASH in children with type 2 diabetes and NAFLD compared with non-diabetic children with NAFLD 7 and a high prevalence of suspected NAFLD based on elevated transaminase levels in children with type 2 diabetes. 8 It has been shown in prior studies that there is an association between increased liver fat accumulation and insulin resistance, 12, 13 , and insulin resistance is widely believed to play a role in the pathogenesis of both NAFLD and type 2 diabetes. The finding of NASH in 60.5% of our study subjects is higher than the 43.2% reported in 44 pediatric subjects with type 2 diabetes enrolled in the NASH CRN, 7 and much higher in comparison with the 22% of NASH in 473 subjects with NAFLD and with normal glucose, 7 which provides further evidence that type 2 diabetes in those with obesity and NAFLD may increase the risk of developing NASH. This is clinically important, as it has been recognized that cirrhosis occurs in 19% to 33% of adults with NASH. While 26% of those with NASH in this cohort had advanced fibrosis (stage 3), cirrhosis (stage 4) was not observed. In the pediatric age cirrhosis is uncommon, being reported in <10% of those with NASH. 7, 14 Prior adult studies have shown increased rates of cirrhosis and mortality in diabetic subjects with NAFLD compared with non-diabetic subjects with NAFLD. 15 In our study, we found that 88% of those diagnosed with NASH per histology had NAS of ≥4. This cutoff was better than using a NAS cutoff of ≥5. Those with NAS ≥4 had higher stage fibrosis than those with NAS < 4. This lends further support to the contention that using a cutoff NAS ≥ 5 to diagnose NASH is not sensitive enough, which has been suggested by prior studies, 11 and our pediatric data support using a NAS ≥ 4 as a more sensitive cutoff. However, NAS cannot replace a pathologist determination of NASH.
The degree of steatosis in our study cohort was significantly correlated with the presence of NASH. This may be clinically significant, as steatosis can be evaluated using magnetic resonance imagingestimated proton density fat fraction (PDFF). 16 A recent study in adults with NASH found that PDFF correlates well with histologic hepatic steatosis grade. 17 If steatosis degree in children is indeed correlated with the presence of NASH, and if steatosis can be estimated using non-invasive PDFF, this may eventually negate the need for invasive liver biopsies in some patients.
Also of note, stage 3 fibrosis was noted in 26.1% of those with NASH, but in none with borderline or no-NASH (Figure 1) . This is important, as prior studies in adults have found that patients with stage 3 fibrosis or cirrhosis had increased mortality, irrespective of NAS or degree of steatosis. 18, 19 The presence of stage 3 fibrosis as early as adolescence in our cohort with type 2 diabetes is concerning.
Metabolic phenotype: Elevated ALT levels have been demonstrated to be more prevalent in type 2 diabetic adolescents than in the general obese pediatric adolescent population. 8 In our study, mean ALT levels were significantly higher in those with NASH vs those without NASH, although there was overlap between the two groups. This finding further contributes to conclusions drawn from previous studies that even children with normal or mildly elevated ALT may have significant liver pathology. 14 Higher A1c levels were also found to significantly correlate with higher NAS in our cohort.
This observation is clinically significant, as it implies that improved glycemic control in type 2 diabetes with NAFLD may reduce the risk of progression to NASH. In addition to A1c, we also found that higher
TGs and lower HDL levels were associated with higher NAS. This is also clinically significant, as these are factors that can be targeted clinically and improved with lifestyle modifications. Increased physical activity helps improve insulin sensitivity even without any decrease in BMI. Improved glycemic control will also improve the dyslipidemia. A recent meta-analysis of the effects of the PPAR gamma agonist pioglitazone (a known insulin sensitizer) showed a tendency in lowering TGs (a small effect) and an increase in HDL. 20 Although pioglitazone has shown some promise as a treatment modality for NASH, it is not considered as standard of care due to weight gain and other potential side effects.
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Subjects with two biopsies: In the eight subjects with repeat biopsies, decreased steatosis, BMI Z-score, TG levels, and transaminase levels were associated with decreased NAS. Subjects were in relatively good glycemic control at their initial biopsy and had no change in their A1c to impact NAS. Because of the small sample size, these correlations were not statistically significant aside from the change in steatosis. However, these findings suggest that improvements in these parameters, primarily through weight loss, may result in decreased NAS over time and may reduce the risk of progression to NASH or progression toward cirrhosis. A larger study is needed to further evaluate the associations suggested by this small subset of subjects.
Comments on metformin use: Most subjects in our study were prescribed metformin, including those with repeat biopsies. In our small cohort with repeat biopsies, NAS and steatosis were stable or improved. Prior studies have suggested that treatment with insulin sensitizers such as metformin, rosiglitazone, or pioglitazone may help to improve NAFLD in type 2 diabetes. [22] [23] [24] [25] The histologic stability or improvement demonstrated by our subjects provides further support to the previous suggestion that metformin may exert beneficial effects on NAFLD that are unrelated to its glycemic actions, and further study is warranted.
Strengths:
The strengths of this study include the unique study population of pediatric patients with type 2 diabetes and histologic confirmation of NASH, instead of reliance on transaminase levels, as in a prior pediatric study. 8 Although our subset of subjects with repeat biopsies was small, it allowed us to evaluate progression of NAFLD in these subjects over time, an advantage that not many studies to date have had and that provides further insight into potential clinical therapeutic targets.
Limitations: Limitations of our study include the relatively small number of subjects, most of which were of Mexican American descent, and particularly the limited number of subjects with repeat biopsies. Additional limitations include those that are inherent in any retrospective chart review, including incomplete data for some subjects, inability to determine causality, and a limited ability to verify compliance with medical treatment.
| CONCLUSIONS
NASH was diagnosed in 61% of subjects, and 88% of those with NASH had NAS ≥ 4. A cutoff of ≥4 was more sensitive and predictive of NASH than a NAS ≥ 5. NAS does not replace the determination of NASH by the pathologist. High NAFLD activity (NAS ≥ 4) is common in pediatric type 2 diabetes (53%), and can be present even with mild transaminase elevation. While mean ALT was lower in those without NASH vs those with NASH on pathology, there was a large overlap.
Lower NAS scores on initial biopsies were noted to be associated with lower TG, lower A1c, and higher HDL, targets that can be improved with diet, exercise, and better diabetes control.
Of those subjects with repeat biopsies, most of whom received metformin, NAS and steatosis was stable or improved. Decreases in BMI Z-score and TG were associated with improvement in NAS over time. This underscores the importance of lifestyle changes in reducing both BMI and TG, and thus potentially helping to address NASH.
However, the small sample size and the effects of outliers make it difficult to draw firm conclusions. It is possible that metformin may exert beneficial effects on NAFLD that are unrelated to its glycemic actions. 
